Tale of three services: early UK experience with mavacamten treatment for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction
Mavacamten treatment was associated with significant symptomatic improvement, reduced LVOT gradients and improved biomarker profiles in patients with oHCM. The implementation of clinical services to deliver mavacamten in the UK should not follow a 'one-size-fits-all' approach but rather leverage the unique strengths of each specific centre.
Authors
- Robert Cooper (ORCID: https://orcid.org/0000-0001-7482-828X)
- Yande Kasolo (ORCID: https://orcid.org/0000-0002-8951-2111)
- Rachel Bastiaenen (ORCID: https://orcid.org/0000-0002-5018-8035)
- Antonio de Marvao (ORCID: https://orcid.org/0000-0001-9095-5887)
- Jason N. Dungu (ORCID: https://orcid.org/0000-0002-6086-6813)
- Nabeel Sheikh (ORCID: https://orcid.org/0000-0002-5905-8907)
- Gerry Carr‐White
- Jane Draper
- Edward Burford
Institutions
- University of Liverpool (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- British Heart Foundation (GB)
- Liverpool Heart and Chest Hospital (GB)
- Thomas Foundation (AU)
- Essex Cardiothoracic Centre (GB)
- Anglia Ruskin University (GB)
- Liverpool John Moores University (GB)
Publication Details
- Journal
- Open Heart
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/openhrt-2025-003218
- Citations
- 3
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.16
Funders
- Bristol-Myers Squibb
- Pfizer